

Management nutrizionale della sarcopenia

Lorenzo M Donini



SAPIENZA
UNIVERSITÀ DI ROMA

Dipartimento di Medicina
Sperimentale

*Sezione di Fisiopatologia Medica,
Scienza dell'Alimentazione ed
Endocrinologia*



Lorenzomaria.donini@uniroma1.it

La sarcopenia in età geriatrica:

- etiopatogenesi**
- conseguenze cliniche e funzionali**

Linee di intervento

Il progetto PROVIDE



La sarcopenia in età geriatrica:


- etiopatogenesi**
- conseguenze cliniche e funzionali

Linee di intervento

Il progetto PROVIDE



The Aging Body




- Body Weight peaks during 5th-6th decade of life and is stable until 65-70 years old²
- Typically, with age comes a loss in lean mass and a gain in fat mass
 - Resulting from innate metabolic changes and increase in sedentary life
- Muscle cell mass declines to the greatest of body cell mass
 - Skeletal muscle begins to decline around 45-55 years old
 - After this age, muscle declines 12-15% per decade until 80
- Bone weakens as a result of aging and corresponds with a decrease in muscle

1. Roubenoff, R. "Sarcopenia: A major modifiable cause of frailty in the elderly." *Journal of Nutrition, Health and Aging*. 4(3):1. 2000.
2. Kinney, John. "Nutritional frailty, sarcopenia and falls in the elderly." *Current Opinion in Clin Nutr and Metab Care*. 7:15-20. 2004
3. Kamel, Hosam. "Sarcopenia and Aging." *Nutrition Reviews*. 61(5): 157-167. 2003.

Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study¹⁻³

Am J Clin Nutr 2005;82:872-8.

Anne B Newman, Jung Sun Lee, Marjolein Visser, Bret H Goodpaster, Stephen B Kritchevsky, Frances A Tylavsky, Michael Nevitt, and Tamara B Harris



Factors that may influence the loss of LBM: **sex hormone steroids, insulin-like growth factor, protein intake, physical activity.**

LBM is associated with muscle strength, bone density, and physical functioning and therefore to disability in old age.

Mean (±SD) percentage changes in lean (■) and fat (□) compartments with weight loss and weight gain over a 4-y period in the Health, Aging and Body Composition Study cohort (n = 2163).




SAPIENZA
UNIVERSITÀ DI ROMA

RESEARCH LETTER

Effect of 10 Days of Bed Rest on Skeletal Muscle in Healthy Older Adults

Kortebein, P. et al. JAMA 2007



24 h muscle protein synthesis during 10 day of inactivity in elderly (stable isotope methodology)

large loss of skeletal muscle as a result of bed rest, (particularly from the lower extremities)

⇐ decline in protein synthesis and strength

⇐ negative N balance (before bed rest despite being on a diet with the RDA for protein, increased during bed rest)


“ the pronounced effect of bed rest alone on skeletal muscle mass and function combined with the physiological stress associated with hospitalization (⇒ nutritional compromise, inflammation) may result in a more substantial loss of muscle size and function for many older adults during hospitalization”



Aging is associated with diminished accretion of muscle proteins after the ingestion of a small bolus of essential amino acids¹⁻³

Christos S Katsanos, Hisamine Kobayashi, Melinda Sheffield-Moore, Asle Aarsland, and Robert R Wolfe

Am J Clin Nutr 2005;82:1065-73




ingestion of a small bolus of EAAs results in diminished muscle protein accretion in elderly persons when compared with young persons.

⇒ important role of the amount of AA ingested in a single occasion, not only the amount of amino acids ingested during the course of a time period (eg, 1 d), as a cause of age-associated muscle protein loss.

The Response of Muscle Protein Anabolism to Combined Hyperaminoacidemia and Glucose-Induced Hyperinsulinemia Is Impaired in the Elderly*

ELENA VOLPI†, BETTINA MITTENDORFER, BLAKE B. RASMUSSEN, AND
ROBERT R. WOLFE



AA alone stimulate muscle protein synthesis in the elderly.

However, mixed nutritional supplementation failed to improve muscle mass.

The failure of mixed nutritional supplementation to increase muscle mass in the elderly depends on specific alterations in the response of muscle to the combined effects of exogenous AA and endogenous insulin.

A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly


Christos S. Katsanos,¹ Hisamine Kobayashi,² Melinda Sheffield-Moore,³ Asle Aarsland,⁴ and Robert R. Wolfe¹

Departments of ¹Surgery and Shriners Hospitals for Children-Galveston, ³Internal Medicine, and ⁴Anesthesiology, University of Texas Medical Branch, Galveston, Texas; and ²AminoScience Laboratories, Ajinomoto Company, Incorporated, Kawasaki, Japan

Am J Physiol Endocrinol Metab 291: E381–E387, 2006.
First published February 28, 2006; doi:10.1152/ajpendo.00488.2005.

- Of EAAs, leucine is the most potent stimulator of muscle protein synthesis
- As with EAAs, the **elderly are less responsive to the stimulatory effect of leucine**

In the elderly an higher dose of leucine is necessary to stimulate muscle protein synthesis






JAMDA

journal homepage: www.jamda.com


Special Article

Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper From the PROT-AGE Study Group

Jürgen Bauer MD ^{a,*}, Gianni Biolo MD, PhD ^b, Tommy Cederholm MD, PhD ^c, Matteo Cesari MD, PhD ^d, Alfonso J. Cruz-Jentoft MD ^e, John E. Morley MB, BCh ^f, Stuart Phillips PhD ^g, Cornel Sieber MD, PhD ^h, Peter Stehle MD, PhD ⁱ, Daniel Teta MD, PhD ^j, Renuka Visvanathan MBBS, PhD ^k, Elena Volpi MD, PhD ^l, Yves Boirie MD, PhD ^m



Aging-related causes of protein shortfall. Such protein deficits have adverse consequences, including impairment of muscular, skeletal, and immune function.



The third Italian National Food Consumption Survey, INRAN-SCAI 2005–06 — Part 1: Nutrient intakes in Italy

S. Sette*, C. Le Donne, R. Piccinelli, D. Arcella, A. Turrini,
C. Leclercq, On Behalf of the INRAN-SCAI 2005–06 Study Group¹

adults (18–64.9 years)	Males (n. 1068)					Females (n. 1245)				
	Mean	SD ^a	Median	5th ^b	95th ^b	Mean	SD ^a	Median	5th ^b	95th ^b
Protein (g/kg body weight) ^c	1.20	0.36	1.15	0.71	1.83	1.25	0.36	1.23	0.71	1.90

elderly (65 years and above)	Males (n. 202)					Females (n. 316)				
	Mean	SD ^a	Median	5th ^b	95th ^b	Mean	SD ^a	Median	5th ^b	95th ^b
Protein (g/kg body weight)	1.15	0.30	1.12	0.70	1.67	1.12	0.32	1.11	0.63	1.69

Mean **protein intake in gram per kilogram** of reported body weight decreased with age.




An independent association between low vitamin D levels and sarcopenia exists

Low vitamin D levels have been associated with:

- reduced muscle mass and strength
- gait impairments
- decreased balance
- increased risk of falls
- long term decline in physical performance




Especialli when 25OHD levels are <75nmol/l



Visser et al., J Clin Endocrinol Metab. 2003; Rolland et al., J Nutr Health Aging 2008; Bischoff-Ferrari, Best Pract Res Cl Rh. 2009; Visvanathan and Chapman, Maturitas 2010; Ceglia, Curr Opin Clin Nutr Metab Care. 2009; Wicherts et al., J Clin Endocrinol Metab 2007







Review

Bone muscle interactions and vitamin D

Jenny E. Gunton^{a,b,c,d,e,*}, Christian M. Girgis^{a,b,c,d}, Paul A. Baldock^{b,e}, Paul Lips^f

- **FGF: fibroblast growth factor**
- **VEGF: vascular endothelial growth factor**





The third Italian National Food Consumption Survey, INRAN-SCAI 2005–06 — Part 1: Nutrient intakes in Italy

S. Sette*, C. Le Donne, R. Piccinelli, D. Arcella, A. Turrini,
C. Leclercq, On Behalf of the INRAN-SCAI 2005–06 Study Group¹

adults (18–64.9 years)	Males (n. 1068)					Females (n. 1245)				
	Mean	SD ^a	Median	5th ^b	95th ^b	Mean	SD ^a	Median	5th ^b	95th ^b
Vitamin D (μg)	2.6	2.3	1.9	0.7	7.7	2.3	2.2	1.5	0.4	7.3

elderly (65 years and above)	Males (n. 202)					Females (n. 316)				
	Mean	SD ^a	Median	5th ^b	95th ^b	Mean	SD ^a	Median	5th ^b	95th ^b
Vitamin D (μg)	2.5	2.4	1.9	0.5	7.5	1.8	1.7	1.4	0.3	6.2

Mean intakes were found to decrease with age from teenagers to adults and to the elderly for phosphorus, zinc, thiamine, riboflavin, vitamin B6, vitamin E, **vitamin D** and vitamin B12.



The Influence of Energy Intake on Protein Metabolism

By H. N. MUNRO AND D. J. NAISMITH
Biochemistry Department, The University, Glasgow

Biochem J. 1953 May; 54(2): 191-197.




Fig. 1. The effect on nitrogen balance of changes in energy intake produced by alterations in dietary carbohydrate. Upper regression line, protein-containing diet (Exp. 1). Lower line (drawn freehand through points), protein-free diet (Exp. 3). Each point is the mean result obtained with four rats.







Fig. 2. The effect on nitrogen balance of changes in energy intake produced by alterations in dietary fat. Upper regression line, protein-containing diet (Exp. 2). Lower regression line, protein-free diet (Exp. 4). Each point is the mean result obtained with five rats (Exp. 2) or four rats (Exp. 4).



Title: PROTEIN REQUIREMENTS FOR THE ELDERLY...

[More details](#)

	FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS	ESN:FAO/WHO/UNU EPR/81/37 August 1981
	WORLD HEALTH ORGANIZATION	
	THE UNITED NATIONS UNIVERSITY	

Provisional Agenda Item 3.3.4

Joint FAO/WHO/UNU Expert Consultation on Energy and Protein Requirements

Rome, 5 to 17 October 1981

PROTEIN REQUIREMENTS FOR THE ELDERLY

Energy intake is of considerable importance in determining an adequate allowance of protein for the elderly: N balance is affected by E balance as well as by protein intake, thus complicating determinations of protein needs from N balance data.





Anthony H. R. Cheng, Ph.D., Ariel Gomez, M.S., James G. Bergan, Ph.D., Tung-Ching Lee, Ph.D., Fernando Monckeberg, M.D., and C. O. Chichester, Ph.D.

- However, it is accepted that older people need smaller E intake and thus the provision of the same caloric intake for older people could lead to a more favorable E balance of the older men that would allow them to retain dietary protein better and thus could mask a greater need.

Protein Nutrition, Exercise and Aging

William J. Evans, PhD



- **L'esercizio fisico di potenza** determina un incremento della massa muscolare derivante dall'aumento relativo della sintesi di proteine rispetto alla loro degradazione.
- Questa risposta all'esercizio fisico di potenza è **ridotta nell'anziano** rispetto al giovane con conseguente riduzione dell'ipertrofia muscolare secondaria all'allenamento.
- in soggetti anziani sottoposti ad esercizio fisico di potenziamento muscolare, si ha una **riduzione del 10-15% dell'escrezione di N** rispetto ai sedentari
- ciò avviene per assunzioni proteica sia di 0.8 g/kg/die che di 1.6 g/kg/die, ad indicare che l'effetto dell'allenamento di potenza sull'utilizzo proteico è indipendente dall'introito proteico stesso.
- Da notare però che nello stesso studio i soggetti con il maggior introito proteico (1.6 g/kg/die), presentavano al termine dell'allenamento **maggior risposta di tipo ipertrofico**, rispetto al gruppo con introito usuale di proteine (0.8 g/kg/die).



Dietary Protein and Resistance Training Effects on Muscle and Body Composition in Older Persons

Wayne W. Campbell, PhD, and Heather J. Leidy, PhD



- resistance exercise and a diet that includes adequate amounts of high-quality proteins are important to reduce the progression of sarcopenia
- resistance training can help improve strength, FFM, muscle mass balance and physical functioning capacities for frail elderly persons
- **older persons may experience a loss of FFM and muscle mass (and therefore subtle metabolic and physiological accommodation responses) with long-term ingestion of 0.8 g /kg/d for protein**, even when they performed resistance training




Fig. 1. Protein intake and fat-free mass changes after three months of resistance training in 50–80 year-old people. Regression equation: $\Delta\text{FFM} = (1.19955 \times \text{protein intake (kg)}) - 1.172$; $r = 0.202$, $P = 0.038$, $n = 106$ men and women.

Frailty in the Elderly: Contributions of Sarcopenia and Visceral Protein Depletion

Theodore B. VanItallie

Metabolism, Vol 52, No 10, Suppl 2 (October), 2003



Sarcopenia (gradual loss of both motor nerves and muscle fibers, particularly of the fast-twitch [IIa] fibers, with impaired function of the surviving myocytes)

- ⇐ **TBP declines** curvilinearly with age, with an accelerated decrease after 65 years (⇐ loss of skeletal muscle protein, visceral protein depletion) (Hansen RD, 2000)
- ⇐ involutional effects of aging-related **hormone changes**
- ⇐ **disuse** arising for the most part from chronic physical inactivity
- ⇐ **inadequate intake of protein and calories** (physiologic anorexia of aging, increase in the level of circulating cytokines, alterations of and release and activity of cholecystokinin)
- ⇒ **increased risk of falling, physical frailty, and disability.**



La sarcopenia in età geriatrica:

- etiopatogenesi
- **conseguenze cliniche e funzionali**

Linee di intervento

Il progetto PROVIDE



Frailty in the Elderly: Contributions of Sarcopenia and Visceral Protein Depletion

Theodore B. VanItallie

Metabolism, Vol 52, No 10, Suppl 2 (October), 2003




- “frailty is characterized by generalized **weakness**, impaired mobility and balance and poor endurance. **Loss of muscle strength** is an important factor in the process of frailty, and is the limiting factor for an individual’s chances of living an independent life until death.” (van den Beld AW, 2000)
- potential causes of frailty include **sarcopenia**, neuroendocrine decline, and immune dysfunction; frailty involves problems or difficulties in different functional domains: physical, **nutritive**, cognitive, and sensory (Strawbridge WJ, 1998)



Frailty in Older Adults: Evidence for a Phenotype


Linda P. Fried,¹ Catherine M. Tangen,² Jeremy Walston,¹ Anne B. Newman,³ Calvin Hirsch,⁴
John Gottdiener,⁵ Teresa Seeman,⁶ Russell Tracy,⁷ Willem J. Kop,⁸ Gregory Burke,⁹
and Mary Ann McBurnie² for the Cardiovascular Health Study
Collaborative Research Group



Musculoskeletal Frailty: A Geriatric Syndrome at the Core of Fracture Occurrence in Older Age

Calcif Tissue Int (2012) 91:161–177

E. Gielen · S. Verschueren · T. W. O'Neill · S. R. Pye · M. D. L. O'Connell ·
D. M. Lee · R. Ravindrarajah · F. Claessens · M. Laurent · K. Milisen ·
J. Tournoy · M. Dejaeger · F. C. Wu · D. Vanderschueren · S. Boonen




Research article

Open Access

Physical function and self-rated health status as predictors of mortality: results from longitudinal analysis in the iSIRENTE study


Matteo Cesari^{*1,2}, Graziano Onder¹, Valentina Zamboni¹, Todd Manini², Ronald I Shorr^{2,3}, Andrea Russo¹, Roberto Bernabei¹, Marco Pahor² and Francesco Landi¹



Kaplan-Meier survival curves for mortality according to the ability to perform the chair stand test and self-rated health (SRH) score.

The Healthcare Costs of Sarcopenia in the United States

Ian Janssen, PhD,^{*†} Donald S. Shepard, PhD,[§] Peter T. Katzmarzyk, PhD,^{†‡} and
Ronenn Roubenoff, MD, MHS* J Am Geriatr Soc 52:80–85, 2004.



The healthcare costs of sarcopenia were estimated based on the effect of sarcopenia on increasing physical disability risk in older persons

\$ 18.5 billion/year
(\$10.8 billion in M, \$7.7 billion in F)
1.5% of total healthcare expenditures for that year



Age 25



Age 63

La sarcopenia in età geriatrica:

- etiopatogenesi**
- conseguenze cliniche e funzionali**

Linee di intervento

Il progetto PROVIDE



How nutritional approach should be characterized to optimize post-prandial anabolic action of dietary proteins?

Increase protein intake

- Meet the age-specific RDAs

Increase amino acid bioavailability

- Distribution of protein intake
- Digestion rate

Use specific substrates

- Leucine
- Vitamin D



Applied nutritional investigation

Long-lasting improved amino acid bioavailability associated with protein pulse feeding in hospitalized elderly patients: A randomized controlled trial

Olivier Bouillanne M.D., Ph.D. ^{a,d,*}, Nathalie Neveux Pharm. D., Ph.D. ^{b,c}, Ioannis Nicolis Ph.D. ^d, Emmanuel Curis Pharm. D., Ph.D. ^d, Luc Cynober Pharm. D., Ph.D. ^{b,c}, Christian Aussel Pharm. D., Ph.D. ^{b,e}

^a Service de Gériatrie 2, Hôpital Émile-Roux, AP-HP, Limeil-Brévannes, France

^b Laboratoire de Biologie de la Nutrition, Université Paris Descartes, Paris, France

^c Service Interhospitalier de Biochimie, AP-HP, Hôpitaux Cochin et Hôtel-Dieu, Paris, France


^d Laboratoire de Biomathématiques, Université Paris Descartes, Faculté de Pharmacie, Paris, France

^e Unité de Nutrition, PUI, AP-HP, Hôpital Henri-Mondor, Créteil, France

- **In a spread diet (SD):** dietary protein was spread over the four daily meals.
- **In a pulse diet (PD):** 72% of dietary protein (averaging 1.31 g/kg body weight daily) was consumed in one meal at noon.


Protein pulse feeding was more efficient than protein spread feeding at increasing plasma postprandial AA concentrations,

Protein pulse feeding was significantly more efficacious than protein spread feeding in improving LM index




 The American Journal of CLINICAL NUTRITION <i>A Publication of the American Society for Nutrition</i> 	
DECEMBER 2010 • VOLUME 92 • NUMBER 6	ISSN 0002-9166
EDITORIALS	
The importance of diet and exercise in the prevention of obesity and type 2 diabetes	1203
Obesity and the environment: a call to action	1205
Obesity and the environment: a call to action	1207
ANNOUNCEMENT FROM THE PRESIDENT OF ASFA	1209
ORIGINAL RESEARCH COMMUNICATIONS	
Cardiovascular disease risk	1211
Cardiovascular disease risk	1213
Cardiovascular disease risk	1215
Cardiovascular disease risk	1217
Cardiovascular disease risk	1219
Cardiovascular disease risk	1221
Cardiovascular disease risk	1223
Cardiovascular disease risk	1225
Cardiovascular disease risk	1227
Cardiovascular disease risk	1229
Cardiovascular disease risk	1231
Cardiovascular disease risk	1233
Cardiovascular disease risk	1235
Cardiovascular disease risk	1237
Cardiovascular disease risk	1239
Cardiovascular disease risk	1241
Cardiovascular disease risk	1243
Cardiovascular disease risk	1245
Cardiovascular disease risk	1247
Cardiovascular disease risk	1249
Cardiovascular disease risk	1251
Cardiovascular disease risk	1253
Cardiovascular disease risk	1255
Cardiovascular disease risk	1257
Cardiovascular disease risk	1259
Cardiovascular disease risk	1261
Cardiovascular disease risk	1263
Cardiovascular disease risk	1265
Cardiovascular disease risk	1267
Cardiovascular disease risk	1269
Cardiovascular disease risk	1271
Cardiovascular disease risk	1273
Cardiovascular disease risk	1275
Cardiovascular disease risk	1277
Cardiovascular disease risk	1279
Cardiovascular disease risk	1281
Cardiovascular disease risk	1283
Cardiovascular disease risk	1285
Cardiovascular disease risk	1287
Cardiovascular disease risk	1289
Cardiovascular disease risk	1291
Cardiovascular disease risk	1293
Cardiovascular disease risk	1295
Cardiovascular disease risk	1297
Cardiovascular disease risk	1299
Cardiovascular disease risk	1301
Cardiovascular disease risk	1303
Cardiovascular disease risk	1305
Cardiovascular disease risk	1307
Cardiovascular disease risk	1309
Cardiovascular disease risk	1311
Cardiovascular disease risk	1313
Cardiovascular disease risk	1315
Cardiovascular disease risk	1317
Cardiovascular disease risk	1319
Cardiovascular disease risk	1321
Cardiovascular disease risk	1323
Cardiovascular disease risk	1325
Cardiovascular disease risk	1327
Cardiovascular disease risk	1329
Cardiovascular disease risk	1331
Cardiovascular disease risk	1333
Cardiovascular disease risk	1335
Cardiovascular disease risk	1337
Cardiovascular disease risk	1339
Cardiovascular disease risk	1341
Cardiovascular disease risk	1343
Cardiovascular disease risk	1345
Cardiovascular disease risk	1347
Cardiovascular disease risk	1349
Cardiovascular disease risk	1351
Cardiovascular disease risk	1353
Cardiovascular disease risk	1355
Cardiovascular disease risk	1357
Cardiovascular disease risk	1359
Cardiovascular disease risk	1361
Cardiovascular disease risk	1363
Cardiovascular disease risk	1365
Cardiovascular disease risk	1367
Cardiovascular disease risk	1369
Cardiovascular disease risk	1371
Cardiovascular disease risk	1373
Cardiovascular disease risk	1375
Cardiovascular disease risk	1377
Cardiovascular disease risk	1379
Cardiovascular disease risk	1381
Cardiovascular disease risk	1383
Cardiovascular disease risk	1385
Cardiovascular disease risk	1387
Cardiovascular disease risk	1389
Cardiovascular disease risk	1391
Cardiovascular disease risk	1393
Cardiovascular disease risk	1395
Cardiovascular disease risk	1397
Cardiovascular disease risk	1399
Cardiovascular disease risk	1401
Cardiovascular disease risk	1403
Cardiovascular disease risk	1405
Cardiovascular disease risk	1407
Cardiovascular disease risk	1409
Cardiovascular disease risk	1411
Cardiovascular disease risk	1413
Cardiovascular disease risk	1415
Cardiovascular disease risk	1417
Cardiovascular disease risk	1419
Cardiovascular disease risk	1421
Cardiovascular disease risk	1423
Cardiovascular disease risk	1425
Cardiovascular disease risk	1427
Cardiovascular disease risk	1429
Cardiovascular disease risk	1431
Cardiovascular disease risk	1433
Cardiovascular disease risk	1435
Cardiovascular disease risk	1437
Cardiovascular disease risk	1439
Cardiovascular disease risk	1441
Cardiovascular disease risk	1443
Cardiovascular disease risk	1445
Cardiovascular disease risk	1447
Cardiovascular disease risk	1449
Cardiovascular disease risk	1451
Cardiovascular disease risk	1453
Cardiovascular disease risk	1455
Cardiovascular disease risk	1457
Cardiovascular disease risk	1459
Cardiovascular disease risk	1461
Cardiovascular disease risk	1463
Cardiovascular disease risk	1465
Cardiovascular disease risk	1467
Cardiovascular disease risk	1469
Cardiovascular disease risk	1471
Cardiovascular disease risk	1473
Cardiovascular disease risk	1475

Am J Clin Nutr. 2011 May;93(5):997-1005.



Supplementation of leucine (with EAA) significantly increases muscle strength (handgrip strenght)



11, 5 g EAA
3.0 g Leucine


Impact of the macronutrient composition of a nutritional supplement on muscle protein synthesis rates in older men: a randomized, double blind, controlled trial

ORIGINAL ARTICLE

JCEM

THE JOURNAL OF CLINICAL
ENDOCRINOLOGY & METABOLISM

Irene Fleur Kramer^{1,3}, Lex B. Verdijk¹, Henrike M. Hamer¹, Sjors Verlaan², Yvette Luiking², Imre W.K. Kouw¹, Joan M. Senden¹, Janneke van Kranenburg¹, Annemarie P. Gijzen¹, Martijn Poeze^{1,3}, Luc J.C. van Loon¹



- **Pro-En:** 21 g of leucine-enriched whey protein with carbohydrate (9 g) and fat (3g)
- **Pro:** isonitrogenous amount of 21 g of leucine-enriched whey protein without carbohydrate and fat
- **En:** an isocaloric mixture (628 kJ) containing carbohydrate and fat only

Supplementation of an adequate amount of dietary protein could be essential to preserve muscle mass in elderly, independent of additional energy.



SAPIENZA
UNIVERSITÀ DI ROMA

Special Article

Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper From the PROT-AGE Study Group

Jürgen Bauer MD^{a,*}, Gianni Biolo MD, PhD^b, Tommy Cederholm MD, PhD^c, Matteo Cesari MD, PhD^d, Alfonso J. Cruz-Jentoft MD^e, John E. Morley MB, BCh^f, Stuart Phillips PhD^g, Cornel Sieber MD, PhD^h, Peter Stehle MD, PhDⁱ, Daniel Teta MD, PhD^j, Renuka Visvanathan MBBS, PhD^k, Elena Volpi MD, PhD^l, Yves Boirie MD, PhD^m

PROT-AGE recommendations for dietary protein intake in *healthy* older adults

- To maintain and regain muscle, older people need **more dietary protein** than do younger people; older people should consume an average daily intake in the range of 1.0 to 1.2 g/kg BW/d.
- The **per-meal anabolic threshold** of dietary protein/amino acid intake is higher in older individuals (ie, 25 to 30 g protein per meal, containing about **2.5 to 2.8 g leucine**) in comparison with young adults.
- **Protein source, timing of intake,** and amino acid supplementation may be considered when making recommendations for dietary protein intake by older adults.
- More research studies with better methodologies are desired to fine tune protein needs in older adults.



Up to 1.2 -1.5 g/Kg/die during acute or chronic diseases

Special Article

Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper From the PROT-AGE Study Group

Jürgen Bauer MD^{a,*}, Gianni Biolo MD, PhD^b, Tommy Cederholm MD, PhD^c, Matteo Cesari MD, PhD^d, Alfonso J. Cruz-Jentoft MD^e, John E. Morley MB, BCh^f, Stuart Phillips PhD^g, Cornel Sieber MD, PhD^h, Peter Stehle MD, PhDⁱ, Daniel Teta MD, PhD^j, Renuka Visvanathan MBBS, PhD^k, Elena Volpi MD, PhD^l, Yves Boirie M

PROT-AGE recommendations on dietary protein and amino acid quality for older people

- The list of indispensable amino acids is qualitatively identical for young and old adults.
- There is no evidence that protein digestion and absorption capacities change significantly with aging.
- “Fast” proteins may have some benefits over “slow” proteins in muscle protein metabolism.
- Dietary enrichment with leucine or a mixture of branched-chain amino acids may help enhance muscle mass and muscle function, but further studies are needed to support specific recommendations.
- β -HMB may attenuate muscle loss and increase muscle mass and strength in older people, but further studies are needed to support specific recommendations.
- Creatine supplementation may be justified for older people, especially those who are creatine-deficient or at high risk of deficiency.

Vitamin D and Sarcopenia/Falls

Joan M. Lappe,^{*,1} and Neil Binkley²

Journal of Clinical Densitometry: Assessment & Management of Musculoskeletal Health, vol. 18, no. 4, 478–482, 2015



- Some small prospective studies do find **vitamin D supplementation to increase type II muscle fiber number and cross-sectional area**.
- In contrast, others find no association of 25(OH)D with muscle mass or strength.
- Meta-analyses are conflicting, finding supplemental vitamin D to have beneficial effects on strength and balance or no effect on strength .
- It is not surprising that meta-analyses have failed to clarify the role of vitamin D inadequacy with muscle function.
 - This lack of clarity likely reflects multiple confounders and design concerns in existing studies.
 - An important limitation of most studies is nonrecognition that the serum 25(OH)D response to vitamin D supplementation is highly variable. It is self-evident that individuals who receive vitamin D supplementation but do not alter their serum 25(OH)D would not be expected to experience a biologic effect.





More than healthy bones: a review of vitamin D in muscle health

S. Bobo Tanner and Susan A. Harwell

Ther Adv Musculoskel Dis

2015, Vol. 7(4) 152–159

- Experimental techniques have allowed detection of the **VDR on skeletal muscle** and in cerebellar tissue
- These data suggest that **vitamin D supplementation** may contribute to the health and maintenance of muscle function.
- The role of vitamin D in muscle health and function remains an exciting and growing area of research with substantial clinical implications.

Nutritional management of Ageing/Frailty



Contributory factors related to nutrition

- Inadequate protein intake
- Increased splanchnic extraction of amino acids
- Decreased muscle response to anabolic stimuli
- Vitamin D deficiency

Nutritional management strategies

- Increase protein intake (1-1.5g/kg)
- Consume high quality or “fast” proteins. AA supplementation
- Increase EAA, in particular leucine, intake
- Increase Vit D intake



La sarcopenia in età geriatrica:

- etiopatogenesi
- conseguenze cliniche e funzionali

Linee di intervento

Il progetto PROVIDE



PROVIDE



SAPIENZA
UNIVERSITÀ DI ROMA

Original Study

Effects of a Vitamin D and Leucine-Enriched Whey Protein Nutritional Supplement on Measures of Sarcopenia in Older Adults, the PROVIDE Study: A Randomized, Double-Blind, Placebo-Controlled Trial

Jürgen M. Bauer MD, PhD^{a,*}, Sjors Verlaan MSc^{b,c}, Ivan Bautmans PhD^d, Kirsten Brandt PhD^e, Lorenzo M. Donini MD, PhD^f, Marcello Maggio MD, PhD^g, Marion E.T. McMurdo MD, PhD^h, Tony Mets MD, PhD^d, Chris Seal PhD^e, Sander L. Wijers PhD^b, Gian Paolo Ceda MD^g, Giuseppe De Vito MD, PhDⁱ, Gilbert Donders MD, PhD^j, Michael Drey MD^k, Carolyn Greig PhD^l, Ulf Holmbäck PhD^m, Marco Narici PhDⁿ, Jamie McPhee PhD^o, Eleonora Poggogalle MD^f, Dermot Power MD, PhD^p, Aldo Scafoglieri PhD^d, Ralf Schultz MD, PhD^q, Cornel C. Sieber MD^r, Tommy Cederholm MD, PhD^m

^a Department of Geriatric Medicine, Carl von Ossietzky University, Oldenburg, Germany

^b Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands

^c Department of Internal Medicine, Section of Gerontology and Geriatrics, VU University Medical Center, Amsterdam, The Netherlands

^d Frailty in Ageing research group (FRIA), Vrije Universiteit Brussel (VUB), Brussels, Belgium

^e Human Nutrition Research Centre, School of Agriculture, Food and Rural Development, Newcastle University Institute for Ageing, Newcastle University, Agriculture Building, Kings Road, Newcastle upon Tyne, United Kingdom

^f Department of Experimental Medicine, Section of Medical Pathophysiology, Endocrinology and Human Nutrition, "Sapienza" University of Rome, Rome, Italy

^g Department of Clinical and Experimental Medicine, Section of Geriatrics, Movement Disorders and Prevention of Disability Unit Food Sciences Unit and Endocrinology of Aging Unit, University of Parma, University Hospital, Parma, Italy

^h Ageing and Health, Ninewells Hospital and Medical School, University of Dundee, Ninewells Hospital, Dundee, United Kingdom

ⁱ Institute for Sport and Health, University College Dublin, Belfield, Dublin, Ireland

^j Femicare, Clinical Research for Women, Tienen, Belgium

^k Medizinische Klinik und Poliklinik IV, Schwerpunkt Akutgeriatrie, Klinikum der Universität München (LMU), Munich, Germany

^l School of Sport, Exercise and Rehabilitation Sciences and Centre for Musculoskeletal Ageing Research, University of Birmingham, Edgbaston, Birmingham, United Kingdom

^m Department of Public Health and Caring Sciences/Clinical Nutrition and Metabolism, Department of Geriatric Medicine, Uppsala University Hospital, Uppsala, Sweden

ⁿ Faculty of Medicine, MRC ARUK Centre for Musculoskeletal Ageing Research, Royal Derby Hospital, University of Nottingham, Derby, United Kingdom

^o School of Healthcare Science, Manchester Metropolitan University, All Saints, Manchester, United Kingdom

^p Department of Medicine for Older Persons, Mater Misericordiae University Hospital and University College Dublin, Belfield, Dublin, Ireland

^q St-Marien Hospital Clinic for Geriatrics, Cologne, Germany

^r Institute for Biomedicine on Ageing, Friedrich-Alexander-University Erlangen-Nürnberg, Nürnberg, Germany

Original Study

Effects of a Vitamin D and Leucine-Enriched Whey Protein Nutritional Supplement on Measures of Sarcopenia in Older Adults, the PROVIDE Study: A Randomized, Double-Blind, Placebo-Controlled Trial

- Multicenter, randomized, controlled, double-blind, 2 parallel-group trial among 380 sarcopenic primarily independent-living older adults
- SPPB scores between 4 and 9, and a low skeletal muscle mass index.
- The **active group** (n= 184) received a vitamin D and leucine-enriched whey protein nutritional supplement to consume twice daily for **13 weeks**.
- The **control group** (n= 196) received an iso-caloric control product to consume twice daily for **13 weeks**.

Table 1
Baseline Demographic and Clinical Characteristics

	Active n = 184	Control n = 196
Age, mean (SD), y	77.3 (6.7)	78.1 (7.0)
Sex, female n (%)	120 (65.2)	129 (65.8)
Living situation, n (%)		
Institutionalized	18 (9.8)	19 (9.7)
Home care	4 (2.2)	10 (5.1)
Living independently	162 (88.0)	167 (85.2)
Mini Mental State Examination, median (IQR)	29.0 (27.0–30.0)	29.0 (28.0–30.0)
Hemoglobin concentration, median (IQR), mmol/L	8.4 (7.9–8.9)	8.5 (8.0–8.9)
BMI, mean (SD), kg/m ²	26.0 (2.5)	26.2 (2.8)
Mini Nutritional Assessment Short-Form (MNA-SF), n (%)		
Malnutrition	1 (0.5)	1 (0.5)
Risk of malnutrition	15 (8.2)	19 (9.7)
No malnutrition	168 (91.3)	176 (89.8)
Protein intake, median (IQR), g/kg body weight/day	1.0 (0.9–1.2)	1.0 (0.8–1.2)
Fasting glucose concentration, median (IQR), mmol/L	5.2 (4.9–5.8)	5.2 (4.9–5.7)
Fasting insulin concentration, median (IQR), mU/L	9.0 (5.0–13.0)	9.0 (6.0–14.0)
Handgrip strength male, median (IQR), kg	26.8 (22.0–30.8)	27.1 (22.0–32.1)
<30 kg, n (%)	45 (70.3)	45 (69.2)
Handgrip strength female, median (IQR), kg	16.5 (13.5–21.5)	16.8 (14.2–20.5)
<20 kg n, (%)	80 (69.6)	94 (74.0)
Gait speed n (%), <0.8 m/s	101 (54.9)	109 (55.6)
SMI (BIA), n (%)		
Normal SMI	0 (0)	0 (0)
Class I sarcopenia*	154 (84)	164 (84)
Class II sarcopenia†	30 (16)	32 (16)
Appendicular muscle mass (DXA), mean (SD), kg	17.9 (4.1)	17.5 (3.8)



PROVIDE

Original Study

Effects of a Vitamin D and Leucine-Enriched Whey Protein Nutritional Supplement on Measures of Sarcopenia in Older Adults, the PROVIDE Study: A Randomized, Double-Blind, Placebo-Controlled Trial

Per serving *	Unit	Active	Control
Energy	kcal	150	150
Protein (from whey protein source)	g	21	0
Essential amino acids	g	10	0
Leucine	g	3	0
Carbohydrates	g	9.4	31.4
Fat	g	3	3
Vitamin D	IU	800	0
Calcium	mg	500	0


RESEARCH

Open Access

Postprandial muscle protein synthesis is higher after a high whey protein, leucine-enriched supplement than after a dairy-like product in healthy older people: a randomized controlled trial


Yvette C Luiking^{1,2}, Nicolaas EP Deutz², Robert G Memelink¹, Sjors Verlaan¹ and Robert R Wolfe^{3*}



- **Prodotto A (W150):** a base di sieroproteine, leucina, 150 Kcal per dose (FortiFit)
- **Prodotto B (W320):** a base di sieroproteine, leucina, 320 Kcal per dose
- **Prodotto C (C150):** a base di caseina, 150 Kcal per dose
- **Prodotto D (C320):** a base di caseina, 320 Kcal per dose



Original Study

Effects of a Vitamin D and Leucine-Enriched Whey Protein Nutritional Supplement on Measures of Sarcopenia in Older Adults, the PROVIDE Study: A Randomized, Double-Blind, Placebo-Controlled Trial





Mean (SD)

Baseline

Change From Baseline, Mean (SD)

Week 7

Week 13

Chair-stand time, s^{††}

Active^{§§}

17.1 (15.2, 21.2)

-1.4 (-3.3-0.4)

-2.5 (-4.2 to -0.6)**

Control^{|||}

17.6 (14.6, 20.6)

-1.0 (-3.0-1.1)

-1.2 (-3.3-0.8)**



PROVIDE

Original Study

Effects of a Vitamin D and Leucine-Enriched Whey Protein Nutritional Supplement on Measures of Sarcopenia in Older Adults, the PROVIDE Study: A Randomized, Double-Blind, Placebo-Controlled Trial

In sarcopenic older adults, 13-week intervention of a vitamin D and leucine-enriched whey protein oral nutritional supplement is effective in improving:

- **Appendicular skeletal muscle mass**
- **Lower-extremity function**
- A specific nutritional supplementation alone might benefit geriatric patients, especially relevant for those who are unable to exercise
- **Nutritional supplementation positively influence measures of sarcopenia and could prevent mobility disability.**

La sarcopenia in età geriatrica:

- etiopatogenesi
- conseguenze cliniche e funzionali

Linee di intervento

Il progetto PROVIDE

Conclusione





ESPEN Guidelines on Enteral Nutrition: Geriatrics ☆

D. Volkert^{a,*}, Y.N. Berner^b, E. Berry^c, T. Cederholm^d, P. Coti Bertrand^e,
A. Milne^f, J. Palmblad^g, St. Schneider^h, L. Sobotkaⁱ, Z. Stanga^j,
DGEM: ☆ ☆ R. Lenzen-Grossimlinghaus, U. Krysz, M. Pirlich, B. Herbst,
T. Schütz, W. Schröer, W. Weinrebe, J. Ockenga, H. Lochs

The administration of ONS has been reported to

- **increase in E and nutrient intake**
- have positive effects on **nutritional status** irrespective of the main diagnosis (even in demented subjects)
- improve **functional status** and **quality of life**
- reduce the risk of developing **pressure ulcers** functional improvements (in several studies)
- reduce **complications** in geriatric patients after hip fracture and orthopaedic surgery
- have significant benefit with respect to **hospital stay** (in some studies)
- increase in **survival**



Impact of Oral Nutritional Supplementation on Hospital Outcomes

VOL. 19, NO. 2

FEBRUARY 2013

■ THE AMERICAN JOURNAL OF MANAGED CARE ■

Tomas J. Philipson, PhD; Julia Thornton Snider, PhD; Darius N. Lakdawalla, PhD;
Benoit Stryckman, MA; and Dana P. Goldman, PhD

Subset of Matched Sample Analyzed	Regression Specification					
	(1)	(2)	(3)	(4)	(5)	(6)
	All	All	Follow-up at least 1 d	Follow-up 1 d to 3 y	Follow-up 1 d to 2 y	Follow-up 1 d to 1 y
Model	OLS	IV	IV	IV	IV	IV
Effect of any ONS use on LOS, d (SE)	2.879 ^b (0.0432)	-2.291 ^b (0.0657)	-1.714 ^b (0.0721)	-2.299 ^b (0.0843)	-2.407 ^b (0.0892)	-2.585 ^b (0.103)
Predicted LOS without ONS, d	8.30	10.88	10.5	10.93	11.07	11.32
Predicted LOS with ONS, d	11.18	8.59	8.79	8.63	8.66	8.74
Change due to ONS use	34.7%	-21.0%	-16.3%	-21.0%	-21.8%	-22.8%
Observations, n	1,160,088	1,160,088	862,960	735,636	670,823	566,682

IV indicates instrumental variable; LOS, length of stay; OLS, ordinary least squares; ONS, oral nutritional supplement; SE, standard error.

^aRegression results were from a sample of ONS episodes matched 1:1 to non-ONS episodes on propensity to receive ONS. Terminal episodes and tube-fed episodes were excluded. The instrument was the fraction of episodes in a given hospital in a given quarter involving ONS use. Standard errors took into account repeated observations of the same individual.

^bSignificant at the 1% level.



SAPIENZA
UNIVERSITÀ DI ROMA



The budget impact of oral nutritional supplements for disease related malnutrition in elderly in the community setting

Karen Freijer^{1*}, Mark J. C. Nuijten² and Jos M. G. A. Schols³

¹ CAPHRI – School for Public Health and Primary Care, Maastricht University, Maastricht, Netherlands

² Ars Accessus Medica, Jisp, Netherlands

³ CAPHRI – School for Public Health and Primary Care, Department of General Practice and Department of Health Services Research, Maastricht University, Maastricht, Netherlands

Table 2 | Costs of DRM in elderly (>60 years) per illness category in community in the Netherlands in 2009 (million Euros)*.

Illness category	Residential home	Home care	Total
Infectious diseases	720.000	1.160.000	1.880.000
Cancer	1.816.765	16.083.713	17.900.478
Endocrinology	971.757	3.215.000	4.186.757
Diabetes	1.228.387	3.215.000	4.443.387
Hematology	230.000	1.520.000	1.750.000
Psychiatry	83.775.896	11.047.385	94.823.280
Neurology	997.523	4.782.222	5.779.745
Dementia	1.394.273	10.294.199	11.688.472
Spinal cord injury	1.193.333	7.173.333	8.366.667
Eye/ear	0	0	0
Cardiovascular	10.206.524	15.590.556	25.797.080
CVA, hemiparesis	13.288.667	16.026.517	29.315.184
Respiratory	3.709.924	8.221.544	11.931.468
Gastro-intestinal	913.889	7.731.331	8.645.220
Urogenital	904.896	0	904.896
Dermatology	436.739	2.446.434	2.883.173
Musculoskeletal	2.976.678	32.377.870	35.354.549
Congenital	0	0	0
Traumata – intoxications	4.849.538	5.143.498	9.993.036
Hip replacement	0	0	0
Total	109.730.125	146.028.603	275.643.390

*Based on cost of care per illness of the Dutch National Institute for Public Health and the Environment (RIVM; Slobbe et al., 2006) indexed to 2009.

Table 3 | Results of the base case analysis: budget impact of ONS (without and with ONS) in elderly with DRM in the community in the Netherlands in 2009 (million Euros).

	Without ONS	With ONS	Savings
Costs of DRM	€ 275.643	€ 205.322	€ 70.321
Costs of ONS	€ 0	€ 57.335	–€ 57.335
Budget impact	€ 275.643	€ 262.657	€ 12.986



**La vieillesse n'est pas si
mauvais quand vous
considérez l'alternative.**

**Maurice Chevalier
(Paris, 1888-1972)**

